Main menu

Determining the fate of engineered tRNAs in human cells by direct RNA sequencing

LC25hamburg_uni

Engineered tRNAs designed to suppress nonsense mutations (sup-tRNAs) have a great therapeutic potential for a variety of genetic diseases. However, the effects of these tRNAs on the cellular translation machinery, particularly their impact on the native tRNA pool, remain unknown.

In this poster, researchers investigate:

  • The use of Oxford Nanopore direct RNA sequencing of the tRNAome to study the effect of sup-tRNAs on them and the fate of these sup-tRNAs in human cells.
  • How these results provide a framework in understanding the effect of these new sup-tRNA therapeutics.
  • New workflows for tRNA analysis to expand the possibilities of RNA sequencing with Oxford Nanopore.
Authors: Rodrigo Alarcon, Daniel Koester, Stine Behrman, Zoya Ignatova from Institute of Biochemistry and Molecular Biology, University of Hamburg.

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Quick links

Intellectual property Cookie policy Corporate reporting Privacy policy Terms, conditions and policies Accessibility

About Oxford Nanopore

Contact us News Media resources & contacts Investor centre Careers BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Spanish flag